Eli Lilly announced it will present important clinical trial data at the 2026 ASCO Annual Meeting, including Phase 3 results for Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive non-small cell lung cancer and Verzenio (abemaciclib) in advanced dedifferentiated liposarcoma. Additional presentations cover investigational therapies like an antibody-drug conjugate targeting Nectin-4 and Kelonia Therapeutics' in vivo CAR-T therapy for multiple myeloma. These findings highlight Lilly's expanding oncology portfolio and ongoing commitment to innovative cancer treatments. The data presentations are expected to influence future cancer treatment approaches and regulatory decisions.
